SNGX - ソリジェニックス (Soligenix Inc.)

SNGXのニュース

   Soligenix Inc Shares Close the Week 30.5% Lower - Weekly Wrap  2021/05/14 22:30:00 Kwhen Finance
Soligenix Inc (SNGX) shares closed this week 30.5% lower than it did at the end of last week. The stock is currently down 30.5% year-to-date, down 43.3% over the past 12 months, and down 56.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.3%. Trading Activity Shares traded as high as $1.12 and as low as $0.85 this week.Shares closed 7e+1% below its 52-week high and 4% above its 52-week low.Trading volume this week was 43.6% lower than the 10-day average and 7.5% lower than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -537.2% The company's stock price performance over the past 12 months lags the peer average by -358.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Graft-Versus-Host Disease (GVHD) Market | Share Analysis and Top Companies Neovii Biotech GmbH, Merck & Co., Inc., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd  2020/11/09 19:19:05 OpenPR
Graft-Versus-Host Disease (GVHD) Market is expected to rise gradually to an estimated value of USD 656.00 million by 2026, registering a CAGR of 6.05% in the forecast period of 2019-2026 with the annual sales of USD 410.00 million in the
   Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results  2020/08/14 11:00:00 PR Newswire
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing…
   TCOM, PII among premarket gainers  2020/07/28 12:16:54 Seeking Alpha
Eastman Kodak (NYSE:KODK) +190%. Spectrum Pharmaceuticals (NASDAQ:SPPI) +52% on positive poziotinib data in lung cancer. Soligenix (NASDAQ:SNGX) +44% on en
   Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Stock Alert: Soligenix Stock Up 45% In Pre Market  2020/04/16 09:29:00 RTT News
Shares of Soligenix Inc. (SNGX) are soaring over 45% in pre-market today, after the company announced an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp.
   Graft-Versus-Host Disease (GVHD) Market | Share Analysis and Top Companies Neovii Biotech GmbH, Merck & Co., Inc., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd  2020/11/09 19:19:05 OpenPR
Graft-Versus-Host Disease (GVHD) Market is expected to rise gradually to an estimated value of USD 656.00 million by 2026, registering a CAGR of 6.05% in the forecast period of 2019-2026 with the annual sales of USD 410.00 million in the
   Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results  2020/08/14 11:00:00 PR Newswire
/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing…
   TCOM, PII among premarket gainers  2020/07/28 12:16:54 Seeking Alpha
Eastman Kodak (NYSE:KODK) +190%. Spectrum Pharmaceuticals (NASDAQ:SPPI) +52% on positive poziotinib data in lung cancer. Soligenix (NASDAQ:SNGX) +44% on en
   Thinking about buying stock in Soligenix Inc, Ekso Bionics, SINTX Technologies, AIM ImmunoTech, or Nio Inc?  2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNGX, EKSO, SINT, AIM, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Stock Alert: Soligenix Stock Up 45% In Pre Market  2020/04/16 09:29:00 RTT News
Shares of Soligenix Inc. (SNGX) are soaring over 45% in pre-market today, after the company announced an agreement for the exclusive worldwide license of CoVaccine HT, a novel vaccine adjuvant, from BTG Specialty Pharmaceuticals, a division of Boston Scientific Corp.

calendar